Company Encyclopedia
View More
name
GH Research
GHRS.US
GH Research PLC, together with its subsidiary, a clinical-stage biopharmaceutical company, engages in developing treatments for depression in the United States. Its lead product candidate is GH001, an inhalable mebufotenin product candidate, which is in phase 2b clinical trial for treating patients with treatment-resistant depression; and in phase 2a clinical trial for treating bipolar II disorder and a current major depressive episode, as well as female patients with postpartum depression. The company also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.
4.514 T
GHRS.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    GH Research Reports GH001 Significantly Reduces Depression and Anxiety in Treatment-Resistant Patients

    GH Research plc announced positive results from a Phase 2b clinical trial of GH001, a synthetic form of mebufotenin, for treatment-resistant depression. The trial showed significant reductions in depression and anxiety symptoms, with improvements in quality of life maintained over six months. The study was presented by Michael E. Thase, and the results were published via EDGAR by GH Research plc.

    Reuters·
    US
    GHRS
    +6.75%
    Reuters·
    US
    GHRS
    +6.75%

    Strategic Advancements and Financial Stability Drive Buy Rating for GH Research

    Analyst Patrick Trucchio of H.C. Wainwright has reiterated a Buy rating for GH Research, lowering the price target to $35.00. This decision is based on the company's strategic advancements and strong financial stability, including $293.9 million in cash and marketable securities. GH Research is progressing well with FDA regulatory engagement, aiming to initiate pivotal trials for GH001 by 2026. Positive data from recent studies supports the company's outlook despite competitive pressures in the psychedelics market. Canaccord Genuity also maintains a Buy rating with the same price target.

    Tip Ranks·
    US
    GHRS
    +6.75%
    Tip Ranks·
    US
    GHRS
    +6.75%

    GH Research (NASDAQ:GHRS) Stock Rating Lowered by Wall Street Zen

    Wall Street Zen downgraded GH Research (NASDAQ:GHRS) from a "hold" to a "sell" rating. Other analysts, including Weiss Ratings and Zacks Research, have also issued negative ratings, while Needham & Company set a "buy" rating with a $19 price target. GH Research has a consensus rating of "Moderate Buy" and a target price of $30.38. The stock traded at $13.50, with a market cap of $702.38 million. Institutional investors hold 56.90% of the stock, and the company focuses on therapies for psychiatric disorders.

    Market Beat·
    US
    GHRS
    +6.75%
    Market Beat·
    US
    GHRS
    +6.75%

    The "Big 4" Psychedelic Compound-Based Drug Discovery Stocks Fell 14% Last Week - Here's Why

    The "BIG 4" psychedelic compound-based drug discovery stocks fell an average of 13.9% in the week ending November 7, following a 9.6% rise in October. Key players include GH Research PLC, COMPASS Pathways, Mind Medicine Inc., and Atai Beckley N.V., each experiencing declines due to various catalysts such as valuation concerns, investor caution, and sector-wide weakness. The economic impact of mental health disorders is significant, with global productivity losses estimated at $1 trillion annually, highlighting the potential market for psychedelic therapies.

    Talkmarkets·
    US
    GHRS
    +6.75%
    US
    CMPS
    +11.59%
    Talkmarkets·
    US
    GHRS
    +6.75%
    US
    CMPS
    +11.59%

    Cantor Fitzgerald Keeps Their Buy Rating on GH Research (GHRS)

    Cantor Fitzgerald analyst Joshua Schimmer has reaffirmed a Buy rating on GH Research (GHRS) with a price target of $25.00. Schimmer, a 5-star analyst with a 15.5% average return and 52.43% success rate, highlights that the consensus on GH Research is a Strong Buy, with an average price target of $29.75.

    Tip Ranks·
    US
    GHRS
    +6.75%
    Tip Ranks·
    US
    GHRS
    +6.75%
    © 2025 Longbridge｜Disclaimer